No Data
No Data
Kanghua Biotech (300841.SZ) received a down payment of US$15 million from HillEvax
Kanghua Biotech (300841.SZ) announced the signing of a recombinant hexavalent norovirus vaccine with HillEvax...
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
Stifel Adjusts HilleVax Price Target to $34 From $30, Maintains Buy Rating
HilleVax (HLVX) has an average rating of Buy and price targets ranging from $21 to $34, according to analysts polled by Capital IQ. Price: 15.72, Change: -0.40, Percent Change: -2.45
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing
Aditya Kohli, Director, around March 18, 2024, sold 18,000 shares in HilleVax (HLVX) for $985,536,428. Following the Form 4 filing with the SEC, Kohli has control over a total of 807,776 shares of the
HC Wainwright & Co. Reiterates Buy on HilleVax, Maintains $28 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates HilleVax with a Buy and maintains $28 price target.
HilleVax Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 73.81% HC Wainwright & Co. → $28 Reiterates Buy → Buy 12/13/2023 73.81% HC Wainwright & Co. → $
No Data